NCT02478463 - Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

Cabotegravir tablet 30 mg once daily for 28 days.

GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237

DRUG

Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase

Trial Locations (2)

15213

GSK Investigational Site, Pittsburgh

21287-5554

GSK Investigational Site, Baltimore